Valeant Canada is a subsidiary of Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, cardio-metabolic, neurology, and branded generics.
Our Canadian commercial operations and the worldwide headquarters of Valeant Pharmaceuticals International, Inc. are located in Laval, Quebec and we have manufacturing facilities in Manitoba, Ontario and Quebec. As leaders in new research and development in dermatology, Valeant Canada is also excited to have established an R&D centre of excellence for consumer dermatology in Laval, Quebec.
The medical dermatology division offers established compounds and brands including Aldara P, BenzaClin, Efudex, Elidel, Loprox, Retin-A-Micro, Topicort, UltraVate,Vyloma, Zovirax and Zyclara.
The ever-growing Valeant dermatology prescription portfolio also includes newer brands such as Aczone, Biacna, and Xerese. Valeant’s most recent launches are Jublia (efinaconazole), a new topical solution for onychomycosis, and the recently re-launched Propaderm (beclomethasone diproprionate), a mid potency topical corticosteroid.
Valeant’s portfolio of prescription therapies for dermatology is complemented by Valeant Aesthetics Canada, offering the Solta Medical and Obagi Medical lines, Valeant Groupe Cosméderme Inc., formerly known as Laboratoire Dr Renaud, offering a full range of cosmeceuticals and Valeant Canada Consumer Products with CeraVe®, the ceramide replenishing skin care product line.